GDA

Summary

GDA (guanine deaminase, HGNC:4212) is a protein-coding gene on chromosome 9q21.13, encoding Guanine deaminase (Q9Y2T3). Catalyzes the hydrolytic deamination of guanine, producing xanthine and ammonia.

This gene encodes an enzyme responsible for the hydrolytic deamination of guanine. Studies in rat ortholog suggest this gene plays a role in microtubule assembly. Multiple transcript variants encoding different isoforms have been found for this gene.

Source: NCBI Gene 9615 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 62 total
• Druggable target: yes — 3 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_004293

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:4212
Approved symbol	GDA
Name	guanine deaminase
Location	9q21.13
Locus type	gene with protein product
Status	Approved
Aliases	CYPIN, GAH
Ensembl gene	ENSG00000119125
Ensembl biotype	protein_coding
OMIM	139260
Entrez	9615

Gene structure

Transcript identifiers

Ensembl transcripts: 11 — 8 protein_coding, 2 nonsense_mediated_decay, 1 protein_coding_CDS_not_defined

ENST00000238018, ENST00000358399, ENST00000376986, ENST00000414671, ENST00000436438, ENST00000475764, ENST00000477618, ENST00000489618, ENST00000545168, ENST00000897996, ENST00000897997

RefSeq mRNA: 7 — MANE Select: NM_004293 NM_001242505, NM_001242506, NM_001242507, NM_001351571, NM_001351572, NM_001351573, NM_004293

CCDS: CCDS56576, CCDS56577, CCDS6641

Canonical transcript exons

ENST00000358399 — 14 exons

Exon	Start	End
ENSE00001624681	72247406	72247433
ENSE00001646828	72248272	72252224
ENSE00001749359	72227943	72228040
ENSE00001760403	72241152	72241298
ENSE00001767251	72245148	72245278
ENSE00001951441	72149440	72149682
ENSE00003501233	72213886	72213991
ENSE00003505039	72202571	72202742
ENSE00003529839	72225677	72225784
ENSE00003591993	72195500	72195588
ENSE00003593023	72219479	72219506
ENSE00003605378	72210687	72210774
ENSE00003625305	72223120	72223227
ENSE00003791573	72231114	72231181

Expression profiles

Bgee: expression breadth ubiquitous, 185 present calls, max score 99.56.

FANTOM5 (CAGE): breadth broad, TPM avg 6.8821 / max 356.3875, expressed in 295 samples.

FANTOM5 promoters (11 alternative TSS)

Promoter ID	TPM avg	Samples expressed
96908	5.3328	254
96909	0.4858	127
96905	0.3844	111
96910	0.3113	91
96906	0.0930	53
96916	0.0795	43
96904	0.0521	24
96915	0.0513	24
96902	0.0500	24
96917	0.0217	9

Top tissues by expression

231 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
ileal mucosa	UBERON:0000331	99.56	gold quality
jejunal mucosa	UBERON:0000399	99.55	gold quality
pancreatic ductal cell	CL:0002079	99.41	gold quality
endothelial cell	CL:0000115	98.60	gold quality
Brodmann (1909) area 46	UBERON:0006483	98.46	gold quality
Brodmann (1909) area 23	UBERON:0013554	98.42	gold quality
kidney epithelium	UBERON:0004819	97.88	gold quality
middle temporal gyrus	UBERON:0002771	97.84	gold quality
entorhinal cortex	UBERON:0002728	97.44	gold quality
superior frontal gyrus	UBERON:0002661	97.33	gold quality
epithelial cell of pancreas	CL:0000083	96.82	gold quality
parietal lobe	UBERON:0001872	95.73	gold quality
postcentral gyrus	UBERON:0002581	95.64	gold quality
duodenum	UBERON:0002114	95.40	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	94.71	gold quality
prefrontal cortex	UBERON:0000451	94.70	gold quality
anterior cingulate cortex	UBERON:0009835	94.26	gold quality
temporal lobe	UBERON:0001871	94.17	gold quality
oviduct epithelium	UBERON:0004804	93.80	gold quality
Brodmann (1909) area 9	UBERON:0013540	93.60	gold quality
frontal cortex	UBERON:0001870	93.53	gold quality
right lobe of liver	UBERON:0001114	93.06	gold quality
neocortex	UBERON:0001950	92.52	gold quality
cerebral cortex	UBERON:0000956	92.43	gold quality
amygdala	UBERON:0001876	92.20	gold quality
liver	UBERON:0002107	91.86	gold quality
Ammon’s horn	UBERON:0001954	91.51	gold quality
islet of Langerhans	UBERON:0000006	91.26	gold quality
nucleus accumbens	UBERON:0001882	91.13	gold quality
occipital lobe	UBERON:0002021	90.79	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	6.44

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

32 targeting GDA, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-196A-1-3P	99.99	72.15	2772
HSA-MIR-485-3P	99.98	70.68	1585
HSA-MIR-539-3P	99.98	70.74	1616
HSA-MIR-7-1-3P	99.91	71.53	4384
HSA-MIR-7-2-3P	99.91	71.40	4394
HSA-MIR-3529-3P	99.90	73.55	3045
HSA-MIR-4495	99.82	72.08	3080
HSA-MIR-202-5P	99.78	67.65	991
HSA-MIR-1208	99.70	68.28	1533
HSA-MIR-4729	99.69	72.18	4233
HSA-MIR-580-3P	99.67	69.23	1841
HSA-MIR-154-3P	99.50	70.05	831
HSA-MIR-487A-3P	99.50	69.95	840
HSA-MIR-4666A-5P	99.41	69.72	1887
HSA-MIR-3182	99.40	68.15	2454
HSA-MIR-4520-2-3P	99.14	69.28	1009
HSA-MIR-3940-5P	99.14	65.26	493
HSA-MIR-4507	99.14	65.27	515
HSA-MIR-4687-5P	99.14	66.26	488
HSA-MIR-4796-3P	99.08	68.38	1681
HSA-MIR-4744	99.01	69.91	1581
HSA-MIR-520G-3P	98.91	67.38	1914
HSA-MIR-520H	98.91	67.38	1914
HSA-MIR-4520-3P	98.75	66.55	963
HSA-MIR-6830-3P	98.62	68.07	1760
HSA-MIR-6773-3P	98.17	65.51	1213
HSA-MIR-7850-5P	98.12	67.28	1111
HSA-MIR-4433A-3P	97.75	62.82	1435
HSA-MIR-3184-3P	96.96	66.91	845
HSA-MIR-617	96.79	65.96	738

Literature-anchored findings (GeneRIF, showing 6)

• the experiments on guanase and nedasin in rat organs performed in this study are considered to have important implications in the investigation of their physiological significance (PMID:16953061)
• since the histochemical staining of guanase and immunohistochemical staining of nedasin overlapped in many regions, guanase is presumed to be involved in signal transduction in organs similar to nedasin (PMID:16953063)
• This protein has been found differentially expressed in thalami from patients with schizophrenia. (PMID:20471030)
• Guanine Deaminase Stimulates Ultraviolet-induced Keratinocyte Senescence in Seborrhoeic Keratosis via Guanine Metabolites. (PMID:32215662)
• Guanine Deaminase in Human Epidermal Keratinocytes Contributes to Skin Pigmentation. (PMID:32517074)
• Long Non-Coding RNA-GDA-1 Promotes Keratinocyte Proliferation and Psoriasis Inflammation by Regulating the STAT3/NF-kappaB Signaling Pathway via Forkhead Box M1. (PMID:36943641)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	gda	ENSDARG00000002986
mus_musculus	Gda	ENSMUSG00000058624
rattus_norvegicus	Gda	ENSRNOG00000018282
drosophila_melanogaster	DhpD	FBGN0261436
caenorhabditis_elegans		WBGENE00000775

Protein

Protein identifiers

Guanine deaminase — Q9Y2T3 (reviewed: Q9Y2T3)

Alternative names: Guanine aminohydrolase, p51-nedasin

All UniProt accessions (5): Q9Y2T3, H0YDZ7, Q5SZC3, Q5SZC5, Q5SZC6

UniProt curated annotations — full annotation on UniProt →

Function. Catalyzes the hydrolytic deamination of guanine, producing xanthine and ammonia.

Subunit / interactions. Homodimer.

Cofactor. Binds 1 zinc ion per subunit.

Pathway. Purine metabolism; guanine degradation; xanthine from guanine: step 1/1.

Similarity. Belongs to the metallo-dependent hydrolases superfamily. ATZ/TRZ family.

Isoforms (3)

UniProt ID	Names	Canonical?
Q9Y2T3-1	1	yes
Q9Y2T3-2	2, c
Q9Y2T3-3	3, a

RefSeq proteins (7): NP_001229434, NP_001229435, NP_001229436, NP_001338500, NP_001338501, NP_001338502, NP_004284* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR006680	Amidohydro-rel	Domain
IPR011059	Metal-dep_hydrolase_composite	Homologous_superfamily
IPR014311	Guanine_deaminase	Family
IPR032466	Metal_Hydrolase	Homologous_superfamily
IPR051607	Metallo-dep_hydrolases	Family

Pfam: PF01979

Enzyme classification (BRENDA):

• EC 3.5.4.3 — guanine deaminase (BRENDA: 28 organisms, 77 substrates, 84 inhibitors, 97 Km, 19 kcat entries)

Substrate kinetics (BRENDA)

8 substrates with measured Km, best-characterized 8. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
GUANINE	0.0026–1.89	79
8-AZAGUANINE	0.0083–1	8
AMMELINE	1.2–2.6	2
1-METHYLGUANINE	0.93	1
5-AMINO-5,6-DIHYDRO[1,2]THIAZOLO[4,3-D]PYRIMIDIN	0.008	1
6-THIOGUANINE	0.8	1
7,8-DIHYDROPTERIN	1.621	1
VALACYCLOVIR	54.6	1

Catalyzed reactions (Rhea), 1 shown:

• guanine + H2O + H(+) = xanthine + NH4(+) (RHEA:14665)

UniProt features (61 total): strand 22, helix 22, binding site 8, turn 4, splice variant 2, chain 1, sequence conflict 1, modified residue 1

Structure

Experimental structures (PDB)

3 structures.

PDB	Method	Resolution (Å)
4AQL	X-RAY DIFFRACTION	1.99
2UZ9	X-RAY DIFFRACTION	2.3
3E0L	X-RAY DIFFRACTION	2.37

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9Y2T3-F1	97.15	0.96

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (8): 82; 84–87; 84; 213–214; 240–243; 240; 330; 330

Post-translational modifications (1): 453

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-74259	Purine catabolism

MSigDB gene sets: 169 (showing top): GAANYNYGACNY_UNKNOWN, TGCACTT_MIR519C_MIR519B_MIR519A, MODULE_418, GAUSSMANN_MLL_AF4_FUSION_TARGETS_A_UP, GOBP_CARBOHYDRATE_DERIVATIVE_CATABOLIC_PROCESS, IVANOVA_HEMATOPOIESIS_LATE_PROGENITOR, GOBP_ORGANOPHOSPHATE_METABOLIC_PROCESS, GOBP_CARBOHYDRATE_DERIVATIVE_METABOLIC_PROCESS, RODRIGUES_NTN1_TARGETS_DN, GOBP_NUCLEOBASE_CONTAINING_SMALL_MOLECULE_METABOLIC_PROCESS, FOSTER_TOLERANT_MACROPHAGE_UP, GOBP_NUCLEOBASE_METABOLIC_PROCESS, GTGTTGA_MIR505, COATES_MACROPHAGE_M1_VS_M2_UP, GOBP_ORGANOPHOSPHATE_CATABOLIC_PROCESS

GO Biological Process (9): allantoin metabolic process (GO:0000255), nucleobase-containing compound metabolic process (GO:0006139), guanine catabolic process (GO:0006147), deoxyguanosine catabolic process (GO:0006161), nervous system development (GO:0007399), obsolete amide catabolic process (GO:0043605), GMP catabolic process (GO:0046038), dGMP catabolic process (GO:0046055), guanine metabolic process (GO:0046098)

GO Molecular Function (5): zinc ion binding (GO:0008270), guanine deaminase activity (GO:0008892), hydrolase activity (GO:0016787), hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds (GO:0016810), metal ion binding (GO:0046872)

GO Cellular Component (1): cytosol (GO:0005829)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Nucleotide catabolism	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
metabolic process	1
primary metabolic process	1
purine nucleobase catabolic process	1
guanine metabolic process	1
2’-deoxyribonucleoside catabolic process	1
purine deoxyribonucleoside catabolic process	1
system development	1
purine ribonucleotide catabolic process	1
purine ribonucleoside monophosphate catabolic process	1
GMP metabolic process	1
purine deoxyribonucleotide catabolic process	1
purine deoxyribonucleoside monophosphate catabolic process	1
dGMP metabolic process	1
purine nucleobase metabolic process	1
transition metal ion binding	1
hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds, in cyclic amidines	1
deaminase activity	1
catalytic activity	1
hydrolase activity	1
cation binding	1
cytoplasm	1
cellular anatomical structure	1

Protein interactions and networks

STRING

1298 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
GDA	DLG4	P78352	917
GDA	DLG3	Q92796	854
GDA	PNP	P00491	789
GDA	APRT	P07741	717
GDA	CRMP1	Q14194	714
GDA	ADA	P00813	710
GDA	STIP1	P31948	707
GDA	DLG1	Q12959	697
GDA	DPYSL2	Q16555	678
GDA	GMPS	P49915	665
GDA	XDH	P47989	627
GDA	SNAPIN	O95295	621
GDA	ADSL	P30566	617
GDA	IMPDH2	P12268	614
GDA	YBX1	P16990	612

IntAct

140 interactions, top by confidence:

A	B	Type	Score
GDA	DLG3	psi-mi:“MI:0407”(direct interaction)	0.740
GDA	DLG3	psi-mi:“MI:0915”(physical association)	0.740
DLG3	GDA	psi-mi:“MI:0915”(physical association)	0.740
DLG3	GDA	psi-mi:“MI:0403”(colocalization)	0.740
TEPSIN	AP4M1	psi-mi:“MI:0914”(association)	0.700
MATN3	TF	psi-mi:“MI:0914”(association)	0.530
SPMIP4	PGK2	psi-mi:“MI:0914”(association)	0.530
HERC3	H3-7	psi-mi:“MI:0914”(association)	0.530
FTH1	A2ML1	psi-mi:“MI:0914”(association)	0.530
STPG2	TF	psi-mi:“MI:0914”(association)	0.530
SH2D4A	TF	psi-mi:“MI:0914”(association)	0.530
ESR1	PGK2	psi-mi:“MI:0914”(association)	0.530
DTX3	ITSN1	psi-mi:“MI:0914”(association)	0.530
GDA	SYNJ2BP	psi-mi:“MI:0407”(direct interaction)	0.440
GDA	PDZD2	psi-mi:“MI:0407”(direct interaction)	0.440
GDA	PATJ	psi-mi:“MI:0407”(direct interaction)	0.440
MAST2	GDA	psi-mi:“MI:0407”(direct interaction)	0.440
GDA	DLG4	psi-mi:“MI:0407”(direct interaction)	0.440
GDA	DLG1	psi-mi:“MI:0407”(direct interaction)	0.440
GDA	PDZK1	psi-mi:“MI:0407”(direct interaction)	0.440
GDA	TAX1BP3	psi-mi:“MI:0407”(direct interaction)	0.440
GDA	PTPN3	psi-mi:“MI:0407”(direct interaction)	0.440
GDA	MAST1	psi-mi:“MI:0407”(direct interaction)	0.440

BioGRID (68): ABAT (Co-fractionation), AMDHD1 (Co-fractionation), AP1G1 (Co-fractionation), ATRIP (Co-fractionation), FAHD1 (Co-fractionation), GDA (Co-fractionation), GDA (Co-fractionation), LARS (Co-fractionation), LCMT2 (Co-fractionation), NPEPL1 (Co-fractionation), TIPRL (Co-fractionation), UBA1 (Co-fractionation), GDA (Affinity Capture-MS), GDA (Affinity Capture-MS), GDA (Affinity Capture-MS)

ESM2 similar proteins: A0A1I9LN01, A0A1U9YI27, B8LWT1, C4JQN7, C5FK77, C5PCN6, C7ZIE1, D4B2N2, D4DEJ7, E5R2Q7, E9CV02, F4J6T7, M1VV65, O04373, O14057, O14124, O48540, O59666, O59832, O64749, O74916, O81641, O94266, O94323, P31428, P31430, P34480, P54969, P54970, Q2UPB0, Q2VQV9, Q3SY69, Q43092, Q4LB35, Q4WVZ3, Q54NU9, Q5RAV9, Q6Q886, Q8GW72, Q8H0B2

Diamond homologs: A0B7V2, A0LMI3, A0RCM7, A1VD37, A3DEQ2, A4FW32, A4J675, A4XJI3, A5D1G6, A5UMN6, A6UQD4, A6UUG9, A6VH76, A7GNR9, A7I6C5, A9A9H3, B0K2W0, B0K8R8, B1I2P4, B5YDN9, B5YLB7, B6YUF8, B7HIQ2, B7HMN9, B7IS56, B7JJI0, B8CX03, B8DKS6, B8E183, B8FRL9, B8J2Q8, C1EPN0, C3L6N3, C3P768, C5BSJ0, C6A048, O27549, O29265, O29701, O31352

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
CREB1	“up-regulates quantity by expression”	GDA	“transcriptional regulation”

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 107 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Dopamine Neurotransmitter Release Cycle	5	34.5×	2e-05
Assembly and cell surface presentation of NMDA receptors	9	31.7×	2e-09
Neurexins and neuroligins	8	21.9×	4e-07
Protein-protein interactions at synapses	5	18.4×	3e-04

GO biological processes:

GO term	Partners	Fold	FDR
establishment or maintenance of epithelial cell apical/basal polarity	9	52.8×	4e-11
receptor clustering	6	37.8×	2e-06
cell-cell adhesion	9	9.2×	8e-05
protein-containing complex assembly	8	9.2×	3e-04

Disease & clinical

Clinical variants and AI predictions

ClinVar

62 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	44
Likely benign	3
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

0 predictions. Top by Δscore:

AlphaMissense

3000 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
9:72210706:G:A	G135E	0.998
9:72245201:G:C	A397P	0.998
9:72248281:G:C	R435P	0.998
9:72202596:G:C	D80H	0.997
9:72202608:C:G	H84D	0.997
9:72202741:T:A	V128D	0.997
9:72225677:A:C	S239R	0.997
9:72225679:C:A	S239R	0.997
9:72225679:C:G	S239R	0.997
9:72228023:T:G	C301W	0.997
9:72241152:A:T	D330V	0.997
9:72202662:T:A	W102R	0.996
9:72202662:T:C	W102R	0.996
9:72210706:G:T	G135V	0.995
9:72213901:G:C	R163P	0.995
9:72245202:C:A	A397D	0.995
9:72202597:A:T	D80V	0.994
9:72202612:C:A	A85D	0.994
9:72210697:T:C	L132P	0.994
9:72223153:T:C	F214L	0.994
9:72223155:T:A	F214L	0.994
9:72223155:T:G	F214L	0.994
9:72228021:T:C	C301R	0.994
9:72241153:C:A	D330E	0.994
9:72241153:C:G	D330E	0.994
9:72247433:G:A	G432R	0.994
9:72247433:G:C	G432R	0.994
9:72248285:T:A	N436K	0.994
9:72248285:T:G	N436K	0.994
9:72149602:G:T	G15W	0.993

dbSNP variants (sampled 300 via entrez): RS1000005537 (9:72237072 G>A,T), RS1000054402 (9:72234657 A>C,G), RS1000083680 (9:72234291 G>A), RS1000086604 (9:72175476 C>A,T), RS1000099774 (9:72236698 C>T), RS1000101191 (9:72221581 G>C,T), RS1000107390 (9:72244465 TAGA>T), RS1000189168 (9:72231206 A>G), RS1000190771 (9:72197157 C>A), RS1000246651 (9:72140362 G>A,C), RS1000273939 (9:72186956 C>T), RS1000298035 (9:72121317 G>A,T), RS1000303987 (9:72227622 T>A), RS1000310161 (9:72165221 C>T), RS1000356511 (9:72155911 A>G)

Disease associations

OMIM: gene MIM:139260 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL3129 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

3 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 313,545 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL113	CAFFEINE	4	200,591
CHEMBL321248	7-METHYLXANTHINE	2	784
CHEMBL792	URIC ACID	2	112,170

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

8 potent at pChembl≥5 of 13 total, top 8 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
5.73	Ki	1880	nM	2,6-DIAMINOPURINE
5.71	Ki	1960	nM	XANTHINE
5.46	Ki	3440	nM	CHEMBL1224659
5.36	Ki	4340	nM	URIC ACID
5.35	Ki	4440	nM	CHEMBL1610
5.30	IC50	5000	nM	AZEPINOMYCIN
5.26	Ki	5550	nM	7-METHYLXANTHINE
5.00	Ki	1e+04	nM	CAFFEINE

PubChem BioAssay actives

8 with measured affinity, of 19 total; 8 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
7H-purine-2,6-diamine	502390: Inhibition of GDA by colorimetric assay	ki	1.8800	uM
3,7-dihydropurine-2,6-dione	502390: Inhibition of GDA by colorimetric assay	ki	1.9600	uM
N-(6-oxo-1,7-dihydropurin-2-yl)acetamide	502390: Inhibition of GDA by colorimetric assay	ki	3.4400	uM
Uric Acid	502390: Inhibition of GDA by colorimetric assay	ki	4.3400	uM
4-amino-1H-imidazole-5-carboxamide	502390: Inhibition of GDA by colorimetric assay	ki	4.4400	uM
6-hydroxy-4,5,6,7-tetrahydro-1H-imidazo[4,5-e][1,4]diazepin-8-one	717436: Inhibition of guanase	ic50	5.0000	uM
7-methyl-3H-purine-2,6-dione	502390: Inhibition of GDA by colorimetric assay	ki	5.5500	uM
Caffeine	1920736: Inhibition of guanine deaminase (unknown origin)	ki	10.0000	uM

CTD chemical–gene interactions

43 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	decreases expression, increases expression, increases methylation	4
Tetrachlorodibenzodioxin	decreases reaction, increases expression	3
sodium arsenite	decreases expression, increases expression	2
Arsenic Trioxide	decreases expression	2
Acetaminophen	decreases expression	2
Tobacco Smoke Pollution	affects expression, increases expression	2
Aflatoxin B1	decreases methylation, increases expression	2
bisphenol A	decreases methylation, increases expression	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
tobacco tar	decreases expression	1
benzo(e)pyrene	increases methylation	1
cupric chloride	increases expression	1
hydroquinone	increases expression	1
S-(1,2-dichlorovinyl)cysteine	affects response to substance, increases expression, affects cotreatment, decreases expression	1
brequinar	increases expression	1
perfluorooctane sulfonic acid	decreases expression	1
CGP 52608	affects binding, increases reaction	1
perfluoro-n-nonanoic acid	decreases expression	1
abrine	decreases expression	1
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide	decreases reaction, increases expression, decreases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Benztropine	affects cotreatment, increases expression	1
Cuprizone	affects cotreatment, increases expression, decreases expression	1
Haloperidol	affects cotreatment, decreases expression	1
Ivermectin	decreases expression	1
Lipopolysaccharides	increases expression, affects cotreatment, decreases expression, affects response to substance	1
Methapyrilene	increases methylation	1
Plant Extracts	affects cotreatment, decreases expression	1
Quercetin	increases expression	1
Ribonucleotides	affects binding	1

ChEMBL screening assays

10 unique, capped per target: 10 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1225626	Binding	Activation of GDA by colorimetric assay	Identification of small molecule compounds with higher binding affinity to guanine deaminase (cypin) than guanine. — Bioorg Med Chem

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B1SR	Abcam HeLa GDA KO	Cancer cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.